NCT05757245招募中1 期
A Phase 1 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Subjects With Transfusion-dependent α-Thalassemia by Transplantation of Autologous CD34+ Cells Transduced Ex Vivo With a Lentiviral Vector (GMCN-508A Drug Product)
First Affiliated Hospital of Guangxi Medical University1 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2023年5月8日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 5
- 试验地点
- 1
- 主要终点
- Percentage of Participants Who Achieved Transfusion Independence (TI)
研究概览
简要总结
This is a non-randomized, open label, single-site, single-dose, phase 1 study in up to 5 participants (between 5 and 35 years of age, inclusive) with Transfusion-dependent α-thalassemia. The study will evaluate the safety and efficacy of autologous hematopoietic stem cell transplantation (HSCT) using GMCN-508A Drug Product [autologous CD34+ hematopoietic stem cells transduced with GMCN-508A lentiviral vector encoding the human α-globin gene].
详细描述
Subject participation for this study will be 5 years.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 5 Years 至 35 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The subject himself/herself or one legal guardian/agent of the subject is required to fully understand the study and voluntarily sign a written informed consent.
- •Ages 5 to 35, no gender limitation.
- •The clinical diagnosis of Transfusion-dependent α-Thalassemia.Transfusion dependence was defined as ≥6 Units of transfusions of pRBCs for the prior 24 weeks without >56 days of non-transfusion.
- •Karnofsky Level of Performance (KPS) score or Lansky Level of Performance (LPS) score ≥
- •Subjects were determined to undergo autologous hematopoietic stem cell transplantation and conditioning procedure by the principle investigator.
- •Subjects were willing to comply with the protocol.
- •Fertile Subjects are willing to take effective contraceptive measures during the study.
排除标准
- •Diagnosed with mild α-thalassemia, Hb Bart's edema, ATRx α-thalassemia, hemoglobin S/β-thalassemia, myelodysplastic subtype anemia, or with HbE homozygous β gene mutation, or with any type of β-thalassemia Thalassemia.
- •Uncorreted Bleeding disorders with frequent bleeding (eg, menorrhagia, epistaxis, coagulation disorders).
- •Bacterial, fungal, parasitic or viral infection as determined by the investigator to be clinically significant.
- •Presence of severe iron overload.
- •Any prior or current malignancy, myeloproliferative disorders or immunodeficiency disorders.
- •Any major medical disease, laboratory test abnormality or mental illness that would render the participant ineligible for the study.
- •Immediate family member with a known Familial Cancer Syndrome.
- •Prior receipt of gene therapy, allogeneic bone marrow transplantation or allogeneic hematopoietic stem cell transplantation.
- •Participation in another clinical study with an investigational drug 3 months prior to Screening.
- •Pregnancy, plan to be pregnant during study or breastfeeding in a postpartum female.
- •Known hypersensitivity to any ingredients or excipients of the test drug.
- •Eligible for allogeneic bone marrow transplantation or allogeneic hematopoietic stem cell transplantation with a known and available donor.
- •Any other condition that would render the participant ineligible for the study, as determined by the investigator.
结局指标
主要结局
Percentage of Participants Who Achieved Transfusion Independence (TI)
时间窗: From time of drug product infusion up to 24 months
TI was defined as a weighted average hemoglobin (Hb) \>= 9 g/dL without any packed red blood cells (pRBC) transfusions for a continuous period of \>=12 months at any time during the study after GMCN-508A Drug Product infusion. Percentage of participants who achieved TI from time of drug product infusion up to 24 months was reported.
次要结局
- Annualized Number of pRBC Transfusions(From 12 to 24 months post drug product infusion)
- Weighted Average Hemoglobin (Hb) During Period of Transfusion Independence (TI)(From time of drug product infusion up to 24 months)
- Change From Baseline in Serum Ferritin(Baseline, Month 12 and 24)
- Percentage of Participants Who Achieved Transfusion Independence (TI) at Month 24(Month 24)
- Duration of Transfusion Independence (TI)(From time of drug product infusion up to 24 months)
- Time From GMCN-508A Drug Product Infusion to Achieving Transfusion Independence (TI)(From time of drug product infusion up to 24 months)
- Change From Baseline in Pediatric Quality of Life Inventory (PedsQL) Generic Core Scale (GCS) Score(Baseline, Month 12 and 24)
- Proportion of Participants With Successful Neutrophil Engraftment(From time of drug product infusion up to 24 months)
- Overall Survival(From time of drug product infusion up to 24 months)
- Incidence of acute and/or chronic graft-versus-host disease (GVHD)(From time of drug product infusion up to 24 months)
- Percentage of Participants with occurrence of malignant disease(From time of drug product infusion up to 24 months)
- Annualized Volume of pRBC Transfusions(From 12 to 24 months post drug product infusion)
- Change From Baseline in Cardiac T2* on MRI(Baseline, Month 12 and 24)
- Proportion of Participants With Successful Platelet Engraftment(From time of drug product infusion up to 24 months)
- Change From Baseline in Short Form-36 Health Survey (SF-36)(Baseline, Month 12 and 24)
- Proportions of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)(From signing of informed consent to 24 months after the drug product infusion)
- Proportion of Participants Who Have Not Received Chelation Therapy for At Least 6 Months Following Drug Product Infusion.(From 6 to 24 months)
- Time to Neutrophil Engraftment(From time of drug product infusion up to 24 months)
- Time to Platelet Engraftment(From time of drug product infusion up to 24 months)
- Change From Baseline in liver Iron Content by Magnetic Resonance Imaging (MRI)(Baseline, Month 12 and 24)
- Transplant-related Mortality(Through 100 and 365 days post GMCN-508A Drug Product infusion)
- Percentage of Participants Detected With Replication-competent Lentivirus (RCL)(From time of drug product infusion up to 24 months)
研究者
Yongrong Lai
MD, Director of Hematology Department of First Affiliated Hospital of Guangxi Medical University
First Affiliated Hospital of Guangxi Medical University
研究点 (1)
Loading locations...
相似试验
撤回
1 期
Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT05248685Beijing Boren Hospital20
Unknown
1 期
Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.Nasopharyngeal CarcinomaNCT04073784Sun Yat-sen University41
Unknown
1 期
NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ TumorsSolid TumorColorectal CancerGliomaHepatocellular CarcinomaNCT04550663The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School10
招募中
1 期
Study Of B7H3 CAR-T Cells in Treating Advanced Liver CancerHepatocellular CarcinomaNCT05323201The Affiliated Hospital of Xuzhou Medical University15
招募中
1 期
NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid TumorPancreatic CancerSolid TumorGastric CancerNCT06134960Peking University12